CytomX Therapeutics announced that management will participate in two upcoming conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 in New York and World ADC London on February 25 in London. The clinical-stage biopharmaceutical company, focused on conditionally activated biologics for oncology, continues to advance its pipeline including varsetatug masetecan and CX-801.

CytomX Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced upcoming presentations of its clinical-stage pipeline including CX-2051 and CX-801, with Phase 1 data updates expected in early 2026.

CytomX Therapeutics will report its third quarter financial results on November 6, 2025, after market close, followed by a conference call and webcast at 5:00 p.m. ET.

Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.

CytomX Therapeutics reported Q2 2025 results with declining revenue, reduced operating expenses, and positive clinical pipeline progress, particularly for its lead colorectal cancer candidate CX-2051.

Calidi Biotherapeutics is developing a groundbreaking genetic medicine platform using engineered viruses to precisely target and treat metastatic cancers, with promising preclinical data presented at AACR and ASCO conferences.

CytomX Therapeutics and Moderna presented preclinical data on an mRNA-encoded masked IL-12 molecule, which showed potent anti-tumor activity with enhanced tolerability.

CytomX Therapeutics, a biopharmaceutical company focused on developing novel conditionally activated biologics for cancer treatment, announced that its CEO will present at the Barclays Global Healthcare Conference. The company's pipeline includes several clinical-stage candidates targeting various cancer types.

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET.

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company’s common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.

Wednesday, CytomX Therapeutics Inc (NASDAQ:CTMX) released initial data from the ongoing CX-904 Phase 1a dose escalation clinical study, demonstrating a favorable safety profile and confirmed anti-cancer activity.  As of April 16, 2024, data cutoff, the Phase 1 study enrolled 35 heavily pretreated patients with advanced metastatic solid tumor types. CX-904 demonstrated a favorable safety profile, supporting administration and monitoring enrolled patients in an outpatient setting. Eight patients had measurable tumor reduction at data cutoff, including 2 of 6 efficacy-evaluable patients (33%) with pancreatic cancer with confirmed partial responses. All six efficacy-evaluable patients with pancreatic cancer achieved disease control (objective response or stable disease).  One patient (6 mg target dose) achieved an 83% tumor reduction for the two patients with a confirmed partial response. The second patient (5 mg target dose) with a confirmed response achieved a 51% ...Full story available on Benzinga.com